Market revenue in 2023 | USD 36.4 million |
Market revenue in 2030 | USD 65.6 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Kits & reagents |
Fastest growing segment | Services |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Kits & Reagents, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.
Kits & reagents was the largest segment with a revenue share of 54.4% in 2023. Horizon Databook has segmented the Middle East & Africa mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
In the Middle East and Africa, the demand for mycoplasma testing is rising due to the expanding biopharmaceutical and biotechnology industries of the region. Countries such as Saudi Arabia, the UAE, and South Africa are investing heavily in healthcare infrastructure and research, necessitating stringent quality control measures to ensure the safety & efficacy of biological products.
The growth of local pharmaceutical manufacturing and the adoption of biosimilars and biologics further drive the need for reliable mycoplasma testing. Government initiatives to promote healthcare innovation and attract international biotech companies are also key factors boosting the growth. These initiatives often include implementing rigorous regulatory standards aligned with global practices, which emphasize the importance of mycoplasma testing.
In addition, partnerships with international firms bring advanced technologies and expertise to the region, enhancing local testing capabilities. As a result, mycoplasma testing is becoming increasingly integral to maintaining high standards in biomedical research and production across the Middle East and Africa.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa mycoplasma testing market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa mycoplasma testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account